Malignant Pleural Effusion
Conditions
Interventions
Control group:Cisplatin intrapleural infusion
experimental group:MTX-microparticles intrapleural infusion
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science & Technology
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) The diagnosis of lung cancer and malignant pleural effusion was confirmed by pathology and / or pleural fluid cytology; (2) The routine surgery or systemic radio/chemotherapy was ineffective, the MPE relapsed, or routine treatment therapy was given up by self-causes; (3)stable vital sign with KPS(Karnofsky Performance Status) index more than 60; (4) 18-70 years old; (5) normal haematopoietic function of bone marrow, no hemorrhagic tendency, blood routine test: HGB>=100g/L, WBC>4.0*10^9/L, PLT>80*10^9/L, serum ALT, AST within 2 times upper limit of normal, BUN within 1.5 time upper limit of normal, creatinine within normal range, normal EKG; (6) agreed to participate in the study and sign an informed consent; (7) without other severe comorbidities.
Exclusion criteria
Exclusion criteria: (1) lactating or pregnant patients; (2) allergy to multiple drugs; (3) with other severe comorbidities or psychological diseases; (4) severe infection; (5) participation in other clinical trials within the recent three months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pleural effusions volum; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pleural effusions character;Karnofsky index;survival;tumor markers in serum and pleural effusion(secondary index); | — |
Countries
China
Contacts
Public ContactYang Jin
Outcome results
None listed